Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT).

Arthritis Res Ther · 2020 · PMC7523309 · PMID 32993799

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline non-significantno p-value reported

Further exploration of depressive symptoms by GEE revealed a (borderline non-significant) larger improvement in CES-D scores in the infliximab group compared to the placebo group after the first 24 weeks (model 1A: B group*time(24) = − 6.63, 95%CI − 13.35 to 0.09, p = 0.05).

also in 434 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.